Active ingredients isolated from

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by colonic mucosal inflammation, compromised intestinal barrier function, and gut microbiota dysbiosis. Current therapies often have significant limitations, including adverse effects, highlighting the need for safer alternatives. Materials: To address this gap, this study investigated the composition and therapeutic activity of PAW and its sequentially fractionated components based on molecular weight: PAW1 (< 3 kDa), PAW2 (3-10 kDa), and PAW3 (> 10 kDa) using membrane separation. Using a dextran sulfate sodium (DSS)-induced UC model in C57BL/6 mice, we compared the effects of unfractionated PA and its fractions (PAW1, PAW2, PAW3) on UC pathology and intestinal flora. Results: Our results demonstrate that PA, PAW1, PAW2, and PAW3 ameliorated key UC-associated pathologic features; notably, the unfractionated PA exhibited superior efficacy compared to its individual fractions. PA treatment significantly mitigated DSS-induced body weight loss, disease activity index scores, and colon shortening. It preserved intestinal mucosal integrity, evidenced by increased goblet cell numbers and elevated expression of tight junction proteins (occludin-1, ZO-1). PA treatment reduced colonic inflammation by significantly downregulating pro-inflammatory mediators (NF-κB-p65, TLR4, MyD88, TNF-α, IL-17A, IFN-γ, MPO, iNOS) and upregulating the anti-inflammatory cytokine IL-10, while IL-4 levels were also modulated. Furthermore, PA treatment attenuated intestinal dysbiosis in UC mice, characterized by an increase in beneficial bacteria (e.g., Conclusion: These findings collectively indicate that the aqueous extract of